FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
The Food and Drug Administration (FDA) has expanded 510(k) clearance for the use of the Xenoview 3T MRI Chest Coil in 3T MRI platforms from GE HealthCare.
The chest coil, which facilitates evaluation of lung ventilation in concert with the hyperpolarized contrast agent Xenoview, was previously cleared by the FDA for use in MRI scanners from Philips and Siemens Healthineers, according to Polarean, the developer of the Xenoview 3T Chest Coil and Xenoview.
Specifically indicated for lung ventilation assessment in adults and pediatric patients 12 years and older, the flexible, single-channel radiofrequency coil is tuned to image Xenon-129 nuclei. Polarean said the clearance facilitates expanded access to hyperpolarized MRI technology for high-risk patients with lung disease.
“Expanding our FDA clearance to include GE HealthCare’s platforms, following our previous clearance for Philips and Siemens systems, ensures that more institutions and clinicians across the U.S. can access our innovative Xenon MRI technology. This expansion further enhances our ability to provide advanced imaging solutions to support patients and clinicians in the detection and ongoing monitoring of lung disease,” added Christopher von Jako, the CEO of Polarean.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
